DEKA Research & Development Corp.

DEKA Research & Development Corp.

Independent R&D lab developing medical devices

Overview

DEKA Research & Development Corp. is a leading engineering R&D lab in Manchester, New Hampshire that develops a wide range of practical technologies and devices. It operates by interdisciplinary teams of engineers, machinists, designers, and technicians who take ambitious ideas and turn them into tangible products using advanced design and manufacturing methods. The company differentiates itself through its culture of hands-on experimentation, diverse project portfolio, and a track record of bringing to market or translating ideas into real-world applications. Its goal is to create technologies with a positive, lasting impact on people’s lives by solving meaningful problems.

About DEKA Research & Development Corp.

Simplify's Rating
Why DEKA Research & Development Corp. is rated
B-
Rated B on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation

Industries

Robotics & Automation

Healthcare

Company Size

501-1,000

Company Stage

N/A

Total Funding

N/A

Headquarters

Manchester, New Hampshire

Founded

1982

Get referred to DEKA Research & Development Corp.

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • October 2025 acquisition of Diatech diabetes IP deepens DEKA’s insulin-delivery moat.
  • July 2025 U.S. launch of twiist gives DEKA a live commercial reference customer.
  • The Emergex partnership expands optionality beyond diabetes into vaccine and immunotherapy delivery.

What critics are saying

  • February 2026 Epstein-review headlines drag Dean Kamen’s reputation onto DEKA’s brand.
  • Sequel still lacks a clear commercial scale-up timeline for twiist, limiting near-term revenue.
  • Failure in diabetes commercialization would leave DEKA dependent on partner-funded projects and Kamen’s capital.

What makes DEKA Research & Development Corp. unique

  • Dean Kamen’s 1982 engineering shop builds regulated drug-delivery hardware, not software demos.
  • DEKA’s twiist pump earned FDA clearance in April 2025 for ages six and older.
  • The 2024 Emergex collaboration shows DEKA’s intradermal platform can serve multiple therapeutic categories.

Help us improve and share your feedback! Did you find this helpful?

Company News

Emergex Vaccines Holding Limited
Jan 16th, 2024
Emergex Announces R&D Collaboration with DEKA Research & Development Corp. for Assessment of Emergex's Immunotherapeutic Candidates with DEKA's Intradermal Therapeutic Applicator

- Emergex has entered into an agreement with DEKA Research & Development ('DEKA') to assess the compatibility of Emergex's T cell-priming set-point immunotherapeutic candidates with DEKA's Intradermal Therapeutic Applicator.

Business Wire
Oct 13th, 2022
Revolutionary And Affordable New Robotics System Makes Debut At 2022 First Global Challenge = A Win For Stem Equity

The XRP robot kits can help democratize robotics by getting younger generations excited about STEM and making the field of robotics more affordable and accessible in all parts of the world. The XRP robot kits can help democratize robotics by getting younger generations excited about STEM and making the field of robotics more affordable and accessible in all parts of the world

Recently Posted Jobs

Sign up to get curated job recommendations

DEKA Research & Development Corp. is Hiring for 27 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify. Browse all jobs →